INTENSITY THERAPEUTICS, INC. Operating Cash Flow
INTENSITY THERAPEUTICS, INC. (INTS) reported Operating Cash Flow of -$4.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.34M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.83M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.40M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.39M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$9.23M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$15.22M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$7.21M.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$5.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.17M 10-Q · filed 2026-08-11 | -$6.57M derived: sum of 3 quarters · filed 2026-08-11 | -$8.95M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$1.83M 10-Q · filed 2026-05-07 | -$4.23M derived: sum of 2 quarters · filed 2026-05-07 | -$6.61M derived: sum of 3 quarters · filed 2026-05-07 | -$9.07M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$4.79M derived: sum of 2 quarters · filed 2026-03-27 | -$7.24M derived: sum of 3 quarters · filed 2026-08-11 | -$9.23M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.84M derived: sum of 2 quarters · filed 2026-08-11 | -$6.83M 10-Q · filed 2025-11-06 | -$9.50M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.45M 10-Q · filed 2026-08-11 | -$7.11M derived: sum of 3 quarters · filed 2026-08-11 | -$11.09M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$1.99M 10-Q · filed 2026-05-07 | -$4.66M derived: sum of 2 quarters · filed 2026-05-07 | -$8.63M derived: sum of 3 quarters · filed 2026-05-07 | -$12.84M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$6.64M derived: sum of 2 quarters · filed 2026-03-27 | -$10.85M derived: sum of 3 quarters · filed 2026-03-27 | -$15.22M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.19M derived: sum of 2 quarters · filed 2025-11-06 | -$12.55M 10-Q · filed 2025-11-06 | -$13.50M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | -$4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$8.58M 10-Q · filed 2025-08-07 | -$9.53M derived: sum of 3 quarters · filed 2025-08-07 | -$14.64M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$4.37M 10-Q · filed 2025-05-13 | -$5.31M derived: sum of 2 quarters · filed 2025-05-13 | -$10.43M derived: sum of 3 quarters · filed 2025-05-13 | -$10.67M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$6.07M derived: sum of 2 quarters · filed 2025-03-13 | -$6.30M derived: sum of 3 quarters · filed 2025-03-13 | -$7.21M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | -$5.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$5.36M derived: sum of 2 quarters · filed 2024-11-13 | -$6.26M 10-Q · filed 2024-11-13 | -$6.26M 10-Q · filed 2023-11-13 | -$7.89M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.14M 10-Q · filed 2024-08-08 | -$1.14M 10-Q · filed 2023-08-14 | -$2.77M derived: sum of 3 quarters · filed 2024-08-08 | -$3.80M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$901.00K 10-Q · filed 2024-05-09 | -$2.54M derived: sum of 2 quarters · filed 2024-05-09 | -$3.56M derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$2.66M derived: sum of 2 quarters · filed 2024-03-14 | -$5.48M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$3.84M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$2.82M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |